KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Operations (2016 - 2025)

Emergent BioSolutions' Cash from Operations history spans 16 years, with the latest figure at 77700000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 197.25% year-over-year to 77700000.0; the TTM value through Dec 2025 reached 170600000.0, up 190.63%, while the annual FY2025 figure was 170600000.0, 190.63% up from the prior year.
  • Cash from Operations reached 77700000.0 in Q4 2025 per EBS's latest filing, up from 2300000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 328100000.0 in Q4 2021 to a low of 184000000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 15455000.0, with a median of 1400000.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: tumbled 831.37% in 2022, then skyrocketed 197.25% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 328100000.0 in 2021, then crashed by 71.72% to 92800000.0 in 2022, then plummeted by 65.41% to 32100000.0 in 2023, then crashed by 348.91% to 79900000.0 in 2024, then surged by 197.25% to 77700000.0 in 2025.
  • Per Business Quant, the three most recent readings for EBS's Cash from Operations are 77700000.0 (Q4 2025), 2300000.0 (Q3 2025), and 106400000.0 (Q2 2025).